Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s002800050614PMID 9118470
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study

  2004cited by this paper
• Selected pharmacologic characteristics of idarubicin and idarubicinol.

  1992cited by this paper
• Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects

  1989cited by this paper
• Reversed-phase liquid chromatographic determination of idarubicin and its 13-hydroxy metabolite in human plasma.

  1989cited by this paper
• Comparative metabolism of daunorubicin and 4-demethoxydaunorubicin in mice and rabbits.

  1986cited by this paper
• Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors.

  1984cited by this paper
• Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.

  1980cited by this paper
• Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model.

  1978cited by this paper

• Sensitive Analysis of Idarubicin in Human Urine and Plasma by Liquid Chromatography with Fluorescence Detection: An Application in Drug Monitoring

  2020cites this paper
• Direct modification of the 5‐HT3 receptor current by some anticancer drugs

  2018cites this paper
• Yokukansan contains compounds that antagonize the 5-HT3 receptor.

  2018cites this paper
• In silicoAcute Myeloid Leukaemia

  2017cites this paper
• Improved stability of lipiodol–drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin

  2016cites this paper
• Modelling and optimisation based drug delivery systems for the treatment of Acute Myeloid Leukemia (AML)

  2013cites this paper
• Functional characterization of drug uptake and metabolism in the heart

  2011cites this paper
• Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 286 Pharmacokinetic-Pharmacodynamic Modelling of Anticancer Drugs Haematological Toxicity and Tumour Response in Hollow Fibres

  2003cites this paper
• Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines

  2003cites this paper
• Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect

  2003cites this paper
• Effect of drugs on the cardiac transport, metabolism and action of Idarubicin: pharmacokinetic and pharmacodynamic modeling

  2002cites this paper
• Pharmacokinetics and toxicity of idarubicin in the rat

  2001cites this paper
• Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats

  2000cites this paper
• Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model.

  1999cites this paper
• Determination of idarubicin and idarubicinol in rat plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.

  1999cites this paper
• Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice

  1998cites this paper